key: cord-0798640-bbgcv8uu
authors: Espinoza, David F.; Wetzler, Lauren; Holland, Nicole; Moodley, Neshen; Ware, JeanAnne; Klion, Amy; Khoury, Paneez
title: COVID-19 Infection in Hypereosinophilic Syndrome: A survey-based analysis
date: 2022-03-03
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2022.02.019
sha: c64c46ad3a635a9349dc4b39b29014d26e6d39eb
doc_id: 798640
cord_uid: bbgcv8uu

nan

The role of eosinophils in COVID-19 infection remains controversial. As in other febrile 29 illnesses, including sepsis and influenza, decreased blood eosinophil levels are frequent in 30 COVID-19 infection and have been associated with increased disease severity 1 . Moreover, 31 retrospective studies of patients with asthma and eosinophilic gastrointestinal disorders 32 suggest that eosinophilia and/or type 2 inflammatory responses may be protective against 33 severe manifestations of COVID-19 infection 2,3 . Although these data led some to suggest early 34 in the pandemic that eosinophil-depleting biologics may be detrimental in COVID-19 infection, 35 published studies examining the association between biologic therapy and the incidence and 36 severity of COVID-19 infections in patients with asthma do not support this hypothesis 4 . 37 Moreover, increased eosinophilic pulmonary inflammation has been reported in patients with 38 fatal COVID-19 infection 5 , consistent with a possible pathogenic role of eosinophils in the most 39 severe cases. who were receiving an eosinophil-lowering biologic (mepolizumab or benralizumab) ( Table 2) . 74 Although the numbers are small, no significant differences in prevalence were detected for any 75 of the medications or medication categories between the HESWELL and HESCOVID+ groups. 

Dear research participant,

We are collecting information regarding experience with COVID-19 testing, symptoms and treatment in patients with hypereosinophilia. In the following survey we will use "you" or "patient" to refer to the participant with hypereosinophilia. Whether or not you have been diagnosed with confirmed COVID-19, we invite you to fill out this survey.

Filling out this survey should take no more than 5-10 minutes of your time. We may contact you again over the next year to gather additional information and/or send you additional surveys.

Note that this survey is best taken on a laptop or desktop computer in one sitting, as you will not be able to return to a partially completed survey. 

If you are filling out this form for a family member or friend with HES, please try your best to fill the form out as accurately as possible. Hereafter "you" will refer to the patient in question.

If you do not know the answer to a question please select "don't know" or "unknown." 

Date of HES diagnosis (year)